Convergence of Pharma, MedTech and HealthTech in Delivering Personalized Medicine

The central premise of the article is that integrating these three domains across the full patient journey; from screening and diagnosis to treatment, monitoring, and follow-up, enables more personalized and effective care. Within this framework, precision medicine takes different forms across sectors. In pharmaceuticals, it often involves genetic testing and companion diagnostics to identify patients most likely to respond to a drug. In MedTech, it includes tailored devices or drug-device combinations, such as transdermal patches or targeted delivery systems. HealthTech acts as the connective layer, enabling continuous data collection, real-time monitoring, and clinical decision support.

Continue reading

Medical Science Liaisons: A key to driving patient access to new therapies

MSLs focus on scientific dialogue rather than promotion, helping ensure that information is shared in a compliant and evidence-based manner. MSLs contribute across the entire product lifecycle, starting from early development, where they build relationships with key opinion leaders, to pre-launch, where they provide the foundation for launch and market access. During launch and post-launch, they support ongoing medical education and the operational planning for real-world evidence generation.

Continue reading

The PhD scientist’s pathway into regulatory affairs

One major strength of this article is its clear focus on actionable career strategies. The article is also highly relevant to the current biomedical workforce. As academic positions become more limited and interdisciplinary collaboration becomes increasingly important, regulatory professionals play a central role in translating scientific discoveries into safe and effective therapies. This aligns closely with the broader goals of precision medicine, where scientific innovation must be integrated with regulatory, clinical, and policy considerations.

Continue reading